DYN
Dyne Therapeutics, Inc.$18.23+0.18 (+1.03%)Prev Close$18.04·MCap$3.01B·P/E—·Vol785.7K·Yield—
▲
Buys (12M)
4
$1.03M
▼
Sells (12M)
20
$48.74M
◆
Net Activity
Net Seller
$47.71M
●
Active Insiders
8
last 12 mo
Over the past 12 months, insider activity at Dyne Therapeutics, Inc. (DYN) has been dominated by selling, with 4 insider purchases totaling $1.03M and 20 insider sales totaling $48.74M. The most recent insider transaction was by Rhodes Jason P (director), who sold $7.10M worth of shares on Apr 27, 2026. Dyne Therapeutics, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $3.01B.
DYN Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Apr 27, 2026 | Rhodes Jason P | director | Sell | 384,549 | $18.47 | $7.10M | 5,221,857 |
| Apr 23, 2026 | Kersten Dirk | director | Sell | 10,952 | $20.01 | $219.2K | 4,199,225 |
| Apr 22, 2026 | Rhodes Jason P | director | Sell | 834,302 | $19.75 | $16.48M0.5% OS | 5,554,904 |
| Apr 21, 2026 | Kersten Dirk | director | Sell | 337,248 | $20.21 | $6.82M | 4,332,799 |
| Apr 17, 2026 | Kersten Dirk | director | Sell | 99,613 | $20.35 | $2.03M | 4,562,546 |
| Apr 3, 2026 | Lucera Erick | officer: Chief Financial Officer | Sell | 5,727 | $18.64 | $106.8K | 125,373 |
| Apr 1, 2026 | Posner Brian S | director | Buy | 2,000 | $17.08 | $34.2K | 15,500 |
| Mar 13, 2026 | Kersten Dirk | director | Sell | 129,672 | $19.52 | $2.53M | 4,644,386 |
| Mar 13, 2026 | Posner Brian S | director | Buy | 2,000 | $19.35 | $38.7K | 13,500 |
| Mar 11, 2026 | Kersten Dirk | director | Sell | 688,788 | $19.09 | $13.15M | 5,285,156 |
| Mar 10, 2026 | Posner Brian S | director | Buy | 3,000 | $15.06 | $45.2K | 11,500+35% |
| Mar 6, 2026 | Cox John | director, officer: CEO & President | Sell | 2,732 | $14.90 | $40.7K | 374,145 |
| Mar 6, 2026 | Friedl-Naderer Johanna | officer: Chief Commercial Officer | Sell | 148 | $14.90 | $2.2K | 154,581 |
| Mar 6, 2026 | Kerr Douglas | officer: Chief Medical Officer | Sell | 904 | $14.90 | $13.5K | 171,606 |
| Dec 5, 2025 | Cox John | CEO & President | Sell | 2,662 | $20.72 | $55.2K | 196,877 |
| Dec 5, 2025 | Friedl-Naderer Johanna | Chief Commercial Officer | Sell | 144 | $20.72 | $3.0K | 94,729 |
| Dec 5, 2025 | Kerr Douglas | Chief Medical Officer | Sell | 880 | $20.72 | $18.2K | 87,510 |
| Sep 9, 2025 | Cox John | CEO & President | Sell | 2,640 | $13.41 | $35.4K | 199,539 |
| Sep 8, 2025 | Friedl-Naderer Johanna | Chief Commercial Officer | Sell | 1,038 | $13.29 | $13.8K | 95,017 |
| Sep 8, 2025 | Kerr Douglas | Chief Medical Officer | Sell | 4,425 | $13.30 | $58.8K | 89,263 |
| Jul 15, 2025 | Cox John | CEO & President | Buy | 100,000 | $9.11 | $911.0K | 242,179+70% |
| Jun 6, 2025 | Cox John | CEO & President | Sell | 4,060 | $13.35 | $54.2K | 142,179 |
| Jun 6, 2025 | Friedl-Naderer Johanna | Chief Commercial Officer | Sell | 146 | $13.35 | $1.9K | 95,911 |
| Jun 6, 2025 | Kerr Douglas | Chief Medical Officer | Sell | 1,342 | $13.35 | $17.9K | 92,815 |
| Mar 13, 2025 | Beskrovnaya Oxana | Chief Scientific Officer | Sell | 2,153 | $11.38 | $24.5K | 195,840 |
| Mar 13, 2025 | Friedl-Naderer Johanna | Chief Commercial Officer | Sell | 143 | $12.12 | $1.7K | 96,057 |
| Mar 13, 2025 | Scalzo Richard William | SVP, Head of Finance & Admin. | Sell | 1,343 | $11.38 | $15.3K | 122,330 |
| Mar 7, 2025 | Beskrovnaya Oxana | Chief Scientific Officer | Sell | 1,094 | $11.83 | $12.9K | 197,993 |
| Mar 7, 2025 | Cox John | CEO & President | Sell | 4,061 | $11.83 | $48.0K | 146,239 |
| Mar 7, 2025 | Kerr Douglas | Chief Medical Officer | Sell | 1,343 | $11.83 | $15.9K | 94,157 |
| Mar 7, 2025 | Scalzo Richard William | SVP, Head of Finance & Admin. | Sell | 917 | $11.83 | $10.8K | 123,673 |
| Feb 25, 2025 | Beskrovnaya Oxana | Chief Scientific Officer | Sell | 2,598 | $13.95 | $36.2K | 199,087 |
| Feb 18, 2025 | Scalzo Richard William | SVP, Head of Finance & Admin. | Sell | 2,488 | $13.95 | $34.7K | 124,590 |
| Dec 11, 2024 | Beskrovnaya Oxana | Chief Scientific Officer | Sell | 2,334 | $28.12 | $65.6K | 201,685 |
| Dec 11, 2024 | Scalzo Richard William | SVP, Head of Finance & Admin. | Sell | 1,455 | $28.12 | $40.9K | 127,078 |
| Dec 10, 2024 | Kersten Dirk | Sell | 136,112 | $29.30 | $3.99M | 5,434,982 | |
| Dec 6, 2024 | Kersten Dirk | Sell | 138,845 | $29.38 | $4.08M | 5,540,463 | |
| Dec 4, 2024 | Kersten Dirk | Sell | 110,933 | $29.50 | $3.27M | 5,706,462 | |
| Nov 18, 2024 | Beskrovnaya Oxana | Chief Scientific Officer | Sell | 2,856 | $28.20 | $80.5K | 137,519 |
| Nov 18, 2024 | Incerti Carlo | Sell | 16,500 | $28.73 | $474.0K | 0Exit | |
| Nov 18, 2024 | Rhodes Jason P | Sell | 782 | $33.10 | $25.9K | 5,697,508 | |
| Nov 18, 2024 | Scalzo Richard William | SVP, Head of Finance & Admin. | Sell | 2,735 | $28.20 | $77.1K | 95,833 |
| Nov 15, 2024 | Kersten Dirk | Sell | 19,732 | $34.14 | $673.7K | 5,786,435 | |
| Oct 22, 2024 | Kersten Dirk | Sell | 13,535 | $35.16 | $475.9K | 73,225 | |
| Oct 18, 2024 | Kersten Dirk | Sell | 36,684 | $35.29 | $1.29M | 99,652-27% | |
| Oct 7, 2024 | Kersten Dirk | Sell | 5,441 | $35.13 | $191.1K | 123,323 | |
| Oct 3, 2024 | Kersten Dirk | Sell | 29,941 | $35.32 | $1.06M | 150,282 | |
| Oct 1, 2024 | Kersten Dirk | Sell | 30,974 | $35.50 | $1.10M | 189,647 | |
| Sep 27, 2024 | Kersten Dirk | Sell | 3,617 | $35.14 | $127.1K | 190,939 | |
| Sep 24, 2024 | Kersten Dirk | Sell | 120,242 | $36.07 | $4.34M | 234,598-34% |
Showing 1–50 of 171
1 / 4
DYN Insider Buying Activity
The following table shows recent insider purchases of Dyne Therapeutics, Inc. (DYN) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Apr 1, 2026 | Posner Brian S | director | Buy | 2,000 | $17.08 | $34.2K | 15,500 |
| Mar 13, 2026 | Posner Brian S | director | Buy | 2,000 | $19.35 | $38.7K | 13,500 |
| Mar 10, 2026 | Posner Brian S | director | Buy | 3,000 | $15.06 | $45.2K | 11,500+35% |
| Jul 15, 2025 | Cox John | CEO & President | Buy | 100,000 | $9.11 | $911.0K | 242,179+70% |
DYN Insider Selling Activity
The following table shows recent insider sales of Dyne Therapeutics, Inc. (DYN) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Apr 27, 2026 | Rhodes Jason P | director | Sell | 384,549 | $18.47 | $7.10M | 5,221,857 |
| Apr 23, 2026 | Kersten Dirk | director | Sell | 10,952 | $20.01 | $219.2K | 4,199,225 |
| Apr 22, 2026 | Rhodes Jason P | director | Sell | 834,302 | $19.75 | $16.48M0.5% OS | 5,554,904 |
| Apr 21, 2026 | Kersten Dirk | director | Sell | 337,248 | $20.21 | $6.82M | 4,332,799 |
| Apr 17, 2026 | Kersten Dirk | director | Sell | 99,613 | $20.35 | $2.03M | 4,562,546 |
| Apr 3, 2026 | Lucera Erick | officer: Chief Financial Officer | Sell | 5,727 | $18.64 | $106.8K | 125,373 |
| Mar 13, 2026 | Kersten Dirk | director | Sell | 129,672 | $19.52 | $2.53M | 4,644,386 |
| Mar 11, 2026 | Kersten Dirk | director | Sell | 688,788 | $19.09 | $13.15M | 5,285,156 |
| Mar 6, 2026 | Cox John | director, officer: CEO & President | Sell | 2,732 | $14.90 | $40.7K | 374,145 |
| Mar 6, 2026 | Friedl-Naderer Johanna | officer: Chief Commercial Officer | Sell | 148 | $14.90 | $2.2K | 154,581 |
| Mar 6, 2026 | Kerr Douglas | officer: Chief Medical Officer | Sell | 904 | $14.90 | $13.5K | 171,606 |
| Dec 5, 2025 | Cox John | CEO & President | Sell | 2,662 | $20.72 | $55.2K | 196,877 |
| Dec 5, 2025 | Friedl-Naderer Johanna | Chief Commercial Officer | Sell | 144 | $20.72 | $3.0K | 94,729 |
| Dec 5, 2025 | Kerr Douglas | Chief Medical Officer | Sell | 880 | $20.72 | $18.2K | 87,510 |
| Sep 9, 2025 | Cox John | CEO & President | Sell | 2,640 | $13.41 | $35.4K | 199,539 |
| Sep 8, 2025 | Friedl-Naderer Johanna | Chief Commercial Officer | Sell | 1,038 | $13.29 | $13.8K | 95,017 |
| Sep 8, 2025 | Kerr Douglas | Chief Medical Officer | Sell | 4,425 | $13.30 | $58.8K | 89,263 |
| Jun 6, 2025 | Cox John | CEO & President | Sell | 4,060 | $13.35 | $54.2K | 142,179 |
| Jun 6, 2025 | Friedl-Naderer Johanna | Chief Commercial Officer | Sell | 146 | $13.35 | $1.9K | 95,911 |
| Jun 6, 2025 | Kerr Douglas | Chief Medical Officer | Sell | 1,342 | $13.35 | $17.9K | 92,815 |
| Mar 13, 2025 | Beskrovnaya Oxana | Chief Scientific Officer | Sell | 2,153 | $11.38 | $24.5K | 195,840 |
| Mar 13, 2025 | Friedl-Naderer Johanna | Chief Commercial Officer | Sell | 143 | $12.12 | $1.7K | 96,057 |
| Mar 13, 2025 | Scalzo Richard William | SVP, Head of Finance & Admin. | Sell | 1,343 | $11.38 | $15.3K | 122,330 |
| Mar 7, 2025 | Beskrovnaya Oxana | Chief Scientific Officer | Sell | 1,094 | $11.83 | $12.9K | 197,993 |
| Mar 7, 2025 | Cox John | CEO & President | Sell | 4,061 | $11.83 | $48.0K | 146,239 |
| Mar 7, 2025 | Kerr Douglas | Chief Medical Officer | Sell | 1,343 | $11.83 | $15.9K | 94,157 |
| Mar 7, 2025 | Scalzo Richard William | SVP, Head of Finance & Admin. | Sell | 917 | $11.83 | $10.8K | 123,673 |
| Feb 25, 2025 | Beskrovnaya Oxana | Chief Scientific Officer | Sell | 2,598 | $13.95 | $36.2K | 199,087 |
| Feb 18, 2025 | Scalzo Richard William | SVP, Head of Finance & Admin. | Sell | 2,488 | $13.95 | $34.7K | 124,590 |
| Dec 11, 2024 | Beskrovnaya Oxana | Chief Scientific Officer | Sell | 2,334 | $28.12 | $65.6K | 201,685 |
| Dec 11, 2024 | Scalzo Richard William | SVP, Head of Finance & Admin. | Sell | 1,455 | $28.12 | $40.9K | 127,078 |
| Dec 10, 2024 | Kersten Dirk | Sell | 136,112 | $29.30 | $3.99M | 5,434,982 | |
| Dec 6, 2024 | Kersten Dirk | Sell | 138,845 | $29.38 | $4.08M | 5,540,463 | |
| Dec 4, 2024 | Kersten Dirk | Sell | 110,933 | $29.50 | $3.27M | 5,706,462 | |
| Nov 18, 2024 | Beskrovnaya Oxana | Chief Scientific Officer | Sell | 2,856 | $28.20 | $80.5K | 137,519 |
| Nov 18, 2024 | Incerti Carlo | Sell | 16,500 | $28.73 | $474.0K | 0Exit | |
| Nov 18, 2024 | Rhodes Jason P | Sell | 782 | $33.10 | $25.9K | 5,697,508 | |
| Nov 18, 2024 | Scalzo Richard William | SVP, Head of Finance & Admin. | Sell | 2,735 | $28.20 | $77.1K | 95,833 |
| Nov 15, 2024 | Kersten Dirk | Sell | 19,732 | $34.14 | $673.7K | 5,786,435 | |
| Oct 22, 2024 | Kersten Dirk | Sell | 13,535 | $35.16 | $475.9K | 73,225 | |
| Oct 18, 2024 | Kersten Dirk | Sell | 36,684 | $35.29 | $1.29M | 99,652-27% | |
| Oct 7, 2024 | Kersten Dirk | Sell | 5,441 | $35.13 | $191.1K | 123,323 | |
| Oct 3, 2024 | Kersten Dirk | Sell | 29,941 | $35.32 | $1.06M | 150,282 | |
| Oct 1, 2024 | Kersten Dirk | Sell | 30,974 | $35.50 | $1.10M | 189,647 | |
| Sep 27, 2024 | Kersten Dirk | Sell | 3,617 | $35.14 | $127.1K | 190,939 | |
| Sep 24, 2024 | Kersten Dirk | Sell | 120,242 | $36.07 | $4.34M | 234,598-34% |
DYN Insiders
Similar Stocks to DYN
VRTX
Vertex Pharmaceuticals Incorporated
$429.19+0.77%
$111.71B
REGN
Regeneron Pharmaceuticals, Inc.
$740.38-0.55%
$77.87B
ALNY
Alnylam Pharmaceuticals, Inc.
$305.79-0.88%
$41.24B
INSM
Insmed Incorporated
$133.47-1.85%
$30.79B
RVMD
Revolution Medicines, Inc.
$146.58+11.18%
$29.51B
UTHR
United Therapeutics Corporation
$566.52-0.06%
$25.13B
MRNA
Moderna, Inc.
$46.88-3.78%
$21.42B
RPRX
Royalty Pharma plc
$49.86+0.42%
$21.20B